Molecular therapy for hepatic injury and fibrosis: Where are we?

doi:10.3748/wjg.v12.i4.509

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 4

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3466)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series.

Item

Count

PDF

385

HTML

2904

Figures (1-1)

177

Sum=3466

Jan 28, 2006 (publication date) through Feb 2, 2025

Times Cited of This Article

Times Cited (55)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastroenterol. Jan 28, 2006; 12(4): 509-515
Published online Jan 28, 2006. doi: 10.3748/wjg.v12.i4.509

Full Size Figure Download Figure

Figure 1 Strategies for the prevention and treatment of hepatic fibrosis. A simplified version of the pathogenesis of hepatic fibrosis is illustrated schematically. At various stages, possible therapeutic strategies are provided in italics. See the text for details. KC = Kupffer cells; ECM = extracellular matrix; HSC = hepatic stellate cells; PDGF = platelet-derived growth factor; ROS = reactive oxygen species; TNF-α = tumor necrosis factor-α; TGF-β = transforming growth factor-β.

Citation: Prosser CC, Yen RD, Wu J. Molecular therapy for hepatic injury and fibrosis: Where are we? World J Gastroenterol 2006; 12(4): 509-515
URL: https://www.wjgnet.com/1007-9327/full/v12/i4/509.htm
DOI: https://dx.doi.org/10.3748/wjg.v12.i4.509